A Disclosure Statement for The Center for Health & Pharmaceutical Law
The Center for Health & Pharmaceutical Law (the "Center") at Seton Hall Law School
is committed to independent, academic inquiry focusing on health and pharmaceutical
law. As a part of Seton Hall University, the Newark-based Law School is a nonprofit
501(c)(3) organization. The University and Law School engage in fundraising from alumni
and other contributors. Remaining committed to examining divergent perspectives on
policy issues related to health and pharmaceutical law and policy is critical to the
mission of the Center.
Law School faculty and Center staff are devoted to academic independence in their
research and transparency in their relationships. As such, funding sources are announced
on all published materials and on the Law School website. Regardless of whether financial
support is received in the form of an endowment, as unrestricted funds or for a specific
project, Law School and Center donors are not involved in the academic work of Law
School professors or Center staff. Grants and donations are only accepted if they
do not limit the faculty's or the Center's ability to carry out research, free of
outside influence and consistent with the Center's mission and values.
The Law School funds the salaries of the tenured faculty affiliated with the Center.
Research and administrative support for the Center are jointly funded through a combination
of Law School funds and through unrestricted funds provided by pharmaceutical companies
and restricted funds provided by a variety of corporations. Companies or entities
of regulated industries are not permitted to designate or allocate any portion of
their financial contribution to the Center toward scholarships awarded to government
employees. Full and partial scholarships for government employees, individuals experiencing
hardship, alumni, and law students are offered solely by the Center and no external
parties will be notified regarding the number of scholarships provided, or the identities
or affiliations of scholarship recipients. This information will remain confidential.
The Center and its faculty assume sole responsibility for the content of its publications
and position statements. The Center does not issue publications or statements on behalf
of any donor or other entity.
The organizations that have provided funding to the Center or to the Law School are
listed below.
Bristol-Myers Squibb provided a $5 million endowment in 2005 in support of The Harvey
Washington Wiley Chaired Professorship in Corporate Governance & Business Ethics.
This position is filled by Professor Stephen Lubben.
In 2006, Sanofi-Aventis provided $500,000 to the Law School in "support and development
of the Center for Health & Pharmaceutical Law and the programs and activities associated
with the Center."
The former Schering-Plough Corporation provided the Law School with a $2.5 million
endowment to establish the Schering-Plough Professor in Health Care Regulation and
Enforcement. The endowment was announced in 2006 and completed in 2010.
In 2008, Purdue Pharma provided $25,000 in unrestricted funding for the Center.
In 2008, Roche provided $50,000 for a symposium sponsored by the Gibbons Institute
of Law, Science & Technology, the Seton Hall Law Review, and the Center on "Preparing
for a Pharmaceutical Response to Pandemic Influenza."
In 2011, the following provided funds in support of "Is a For-Profit Structure a Viable
Alternative for Catholic Health Care Ministry?":
Alvarez & Marsal - $5,000
Ardent Health Services - $25,000
Bass, Berry & Sims, PLC - $5,000
Cardinal Health - $1,000
Catholic Health Partners - $10,000
Catholic Healthcare West - $5,000
Ernst & Young, LLP - $2,500
Saint Peter's Healthcare System - $8,000
SSM Health Care - &7,500
University of St. Thomas - $15,000
In 2013, Johnson & Johnson provided $50,000 in unrestricted support to the Center
in support of its educational mission. The company additionally provided $100,000
in unrestricted support to the Center in each of 2011 and 2012. In 2010, Johnson &
Johnson provided $50,000 in unrestricted funds to the Center. In 2009, the company
provided $100,000 as seed funding for two projects: (i) a program on "Strategies for
Compliance Professionals: Honing Decision-Making Skills," and (ii) creation and implementation
of an international compliance program. In 2008, Ortho-McNeil Janssen Scientific Affairs,
a subsidiary of Johnson & Johnson, provided $49,900 in unrestricted funds. Johnson
& Johnson provided $50,000 in 2007 and $100,000 in 2006 in unrestricted funds to support
the Center. Two of Johnson & Johnson's subsidiaries, Centocor, Inc., and Ortho Biotech,
provided $125,000 in unrestricted funding to the Center in 2007.
In 2013, the New Jersey Health Care Quality Institute provided $21,250 to Professor
John Jacobi for research related to the Affiliated Accountable Care Organizations.
In 2013, Microsoft provided $30,000 to support HIPAA related work.
In 2014, the Robert Wood Johnson Foundation provided $200,000 to support Professor
John Jacobi's "QHP Market Behavior: Sentinel Report" designed to examine provision
of benefits under the Affordable Care Act.
In 2016, Janssen, a subsidiary of Johnson & Johnson, provided $108,000 to support
the project, “Ethical Issues in Marketing Pharmaceuticals in Emerging Healthcare Systems.”
